Barclays Turns Positive on Cranswick Citing Protein Trends and Strengthening Home Dining Market

Barclays has started coverage on Cranswick (CWK) with an overweight stance, putting a price target at 63.80 pence. The bank points to Cranswick's disciplined capital spending, tailwinds from increased protein consumption, and a shift towards at-home dining as reasons for its positive outlook.

The bank forecasts Cranswick's pre-tax profit to grow at a 6% compound annual rate from fiscal 2026 through 2029, down from a more rapid 14% pace seen over the previous six years. Meanwhile, revenue and earnings per share are expected to climb 5% and 6% annually in that next phase. Barclays also anticipates a dividend yield around 2%, translating to an approximate total shareholder return of 8%.

Barclays' bullish thesis leans heavily on Cranswick's consistent capital investments. Over the past three years, Cranswick has maintained a pre-tax return on capital employed of 18.5%, with capital expenditures running close to half of EBITDA. Since 2019, the company has committed roughly £811 million to assets and £225 million on acquisitions, underlining its growth-focused approach.

The rise in health-conscious eating and the uptick in GLP-1 medication-which encourages higher protein intake-are spotlighted as growth drivers that will boost demand for affordable animal protein products. Barclays sees this trend as a long-term tailwind supporting Cranswick's market position.

Another factor cited is Cranswick's strong connection to food retailers, accounting for about 79% of its revenue. With consumer budgets feeling the squeeze in the UK, at-home meal consumption has gained ground over dining out. This shift has potentially repositioned Cranswick to capitalize on evolving consumer spending habits.

Using a 20-times price-to-earnings multiple on fiscal 2027 earnings, Barclays' 63.80 pence price target implies a premium valuation compared to the broader UK market, though it aligns with Cranswick's decade-long average multiples. Their optimistic scenario projects a fair value of £86.05-more than 50% above current levels-if Cranswick can replicate its recent growth trajectory and command a higher earnings multiple.

Conversely, Barclays' downside case assumes stagnating revenues and margin pressure, leading to a fair value near £36.25. This suggests a risk of value erosion of around 35% should adverse conditions materialize.

The report acknowledges some clear hazards facing Cranswick, including potential food safety incidents that might turn customers away, rising pricing pressures from retailers, vulnerability to commodity price swings, stiff competition from well-capitalized rivals, and a possible recession dampening supermarket sales.

Despite the positive initiation, Barclays notes that Cranswick is already well covered and favored among many sell-side analysts. The company is also known for its conservative guidance and tendency to exceed expectations, which might factor into its market perception and valuation.